VectorY Therapeutics and Shape Therapeutics, both private firms Announce Option and License Agreement to Advance Vectorized Antibodies for the treament of Neurodegenerative Diseases Using an AAV5-Derived CNS Capsid
September 18, 2025
0
VectorY Therapeutics in the NEWS September 18, 2025 – VectorY Therapeutics, a biotechnology company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, and Shape Therapeutics Inc., a biotechnology company harnessing AI and RNA technologies to engineer next-generation genetic medicines, announced Today that they have entered into an option and license agreement. The Agreement The agreement grants VectorY an exclusive option to evaluate …